Live: every CISA KEV add, FDA letter, ICS-MA advisory, and 524B move for MedTech manufacturers.
One short email covering the previous week's notable items. No fluff.
Successful exploitation of this vulnerability could allow an attacker to modify .fsa/.hid output files, tampering with DNA data and resulting in inaccurate test results.
Successful exploitation of these vulnerabilities could allow an attacker to write files, access unauthorized information, exhaust memory, or crash affected DCMTK client or server processes.
Successful exploitation of this vulnerability in a custom integration version could allow an attacker to steal an authenticated clinician's token via a crafted link.
Successful exploitation of this vulnerability could allow an unauthenticated attacker to write to arbitrary file paths.
Successful exploitation of this vulnerability could allow an attacker to read and write arbitrary handle values and change clinical readings, which could result in taking control of the device and lead to patient harm.
Successful exploitation of this vulnerability could allow an attacker to gain full access to functionality and data with the bioreactor.
Successful exploitation of these vulnerabilities could allow an attacker to obtain sensitive health-related information and prevent legitimate users from establishing a connection with the device.
